NEWS | BEAM Alliance

NEWS

Antabio Awarded $4.4 Million from CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients

Antabio’s Pseudomonas Elastase Inhibitor (PEi) has the potential to significantly enhance the effectiveness of current CF therapy

Labège, France, 2nd January 2020, Antabio SAS, the biopharmaceutical company focused on developing a broad pipeline of antibacterial treatments against life threatening WHO critical priority pathogens, announces today that it has been awarded up to $4.4 million in a second tranche funding from CARB-X, the global nonprofit partnership dedicated to tackling the global rising threat of drug-resistant bacteria. The funding is to support the development of Antabio’s novel small molecule candidate for the treatment of Pseudomonas aeruginosa infections in Cystic Fibrosis (CF) patients.

Full PR available here